Management of Psoriatic Arthritis

Targeted Treatment of the Rheumatic Diseases

Volumn , Issue , 2010, Pages 55-69

  Gladman, Dafna D ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960014672     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-9993-2.00006-0     Document Type: Chapter

References (112)

1. Taylor W.J., Gladman D.D., Helliwell P.S., Marchesoni A., Mease P., Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673.
2. Chandran V., Schentag C.T., Gladman D.D. Sensitivity of the Classification of Psoriatic Arthritis (CASPAR) Criteria in early psoriatic arthritis. Arthritis Rheum 2007, 57:1560-1563.
3. Chandran V., Schentag C.T., Gladman D.D. Sensitivity and specificity of the CASPAR Criteria for Psoriatic Arthritis when applied to patients attending a Family Medicine Clinic. J Rheumatol 2008, 35:2069-2070.
4. D'Angelo S., Ferrante M.C., Atteno M., Cauli A., Rotunno L., Vasile M., et al. The performance of CASPAR criteria in early psoriatic arthritis: preliminary results from an Italian prospective multicentre study. Ann Rheum Dis 2008, 67(Suppl. 2):525.
5. Peloso P.M., Behl M., Hull P., Reeder B. The Psoriasis & Arthritis Questionnaire (PAQ) in detection of arthritis among patients with psoriasis. Arthritis Rheum 1997, 40(Suppl. 9):S64.
6. Alenius G.M., Stenberg B., Stenlund H., Lundblad M., Dahlqvist Rantapää S. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of psoriatic and arthritic questionnaire. J Rheumatol 2002, 29:2577-2582.
7. Husni M.E., Meyer K.H., Cohen D.S., Mody E., Qureshi A.A. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007, 57:581-587.
8. Gladman D.D., Schentag C.T., Tom B.D., Chandran V., Brockbank J., Rosen C.F., et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009, 68:497-501.
9. Alamanos Y., Voulgari P.V., Drosos A.A. Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 2008, 35:1354-1358.
10. Jajic J. Blue-coloured skin over involved joints in psoriatic arthritis. Clin Rheumatol 2001, 20:304-305.
11. Moll J.M., Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55-78.
12. Helliwell P.S., Hetthen J., Sokoll K., Green M., Marchesoni A., Lubrano E., et al. Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model. Arthritis Rheum 2000, 43:865-871.
13. Kane D., Greaney T., Bresnihan B., Gibney R., FitzGerald O. Ultrasonography in the diagnosis and management of psoriatic dactylitis. J Rheumatol 1999, 26:1746-1751.
14. Olivieri I., Barozzi I., Favaro L., Pierro A., de Matteis M., Borghi C., et al. Dactylitis in patients with seronegative spondyloarthropathy: assessment by ultrasonography and magnetic resonance imaging. Arthritis Rheum 1996, 39:1524-1528.
15. Olivieri I., Barozzi I., Pierro A., De Matteis M., Padula A., Pavlica P. Toe dactylitis in patients with spondyloarthropathy: assessment by magnetic resonance imaging. J Rheumatol 1997, 24:926-930.
16. Brockbank J., Stein M., Schentag C.T., Gladman D.D. Characteristics of dactylitis in psoriatic arthritis (PsA). Ann Rheum Dis 2005, 62:188-190.
17. Kane D., Stafford L., Bresniham B., Fitzgerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003, 42:1460-1468.
18. Cantini F., Salvarani C., Olivieri I., Macchioni L., Niccoli L., Padula A., et al. Distal extremity swelling with pitting edema in psoriatic arthritis: a case-control study. Clin Exp Rheumatol 2001, 19:291-296.
19. Fernández-Sueiro J.L., Willisch A., Pinto J., Pertega S., Freire M., Aldo F., et al. Prevalence and location of enthesitis in ankylosing spondylitis and psoriatic arthritis. Ann Rheum Dis 2007, 66(Suppl. 2):98.
20. Gladman D.D. Axial disease in psoriatic arthritis. Current Rheumatology Report 2007, 9:455-460.
21. Gladman D.D., Brubacher B., Buskila D., Langevitz P., Farewell V.T. Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Genetic and gender effects. Clin Invest Med 1993, 16:1-7.
22. Helliwell P.S., Hickling P., Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis?. Ann Rheum Dis 1998, 57:135-140.
23. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370:263-271.
24. Gladman D.D., Anhorn K.B., Schachter R.K., Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986, 13:586-592.
25. Mease P.J. Assessment tools in psoriatic arthritis. J Rheumatol 2008, 35:1426-1430.
26. Gladman D.D., Inman R., Cook R., Maksymowych W.P., Braun J., Davis J.C., et al. International spondyloarthritis interobserver reliability exercise-The Inspire Study: II. Assessment of peripheral joints, enthesitis and dactylitis. J Rheumatol 2007, 34:1740-1745.
27. Chandran V., Cook R., Helliwell P., Kavanaugh A., McHugh N., Mease P., et al. International Multi-centre Psoriasis and psoriatic Arthritis Reliability Trial (GRAPPA-IMPART): assessment of skin, joints, nails and dactylitis. Arthritis Rheum 2007, 56(Suppl. 9):S798.
28. Gladman D.D., Inman R., Cook R., van der Heijde D., Landewé R.B., Braun J., et al. International spondyloarthritis interobserver reliability exercise-The Inspire Study: I. Assessment of spinal measures. J Rheumatol 2007, 34:1733-1739.
29. Menter A., Gottlieb A., Feldman S.R., Van Voorhees A.S., Leonardi C.L., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008, 58:826-850.
30. Cassell S.E., Bieber J.D., Rich P., Tutuncu Z.N., Lee S.J., Kalunian K.C., et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007, 34:123-129.
31. Clegg D.O., Reda D.J., Mejias E., Cannon G.W., Weisman M.H., Taylor T., et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996, 39:2013-2020.
32. Gladman D.D., Helliwell P., Mease P.J., Nash P., Ritchlin C., Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004, 50:24-35.
33. Fransen J., Antoni C., Mease P.J., Uter W., Kavanaugh A., Kalden J.R., et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006, 65:1373-1378.
34. Gladman D.D., Shuckett R., Russell M.L., Thorne J.C., Schachter R.K. Psoriatic arthritis-clinical and laboratory analysis of 220 patients. Quart J Med 1987, 62:127-141.
35. Gladman D.D., Stafford-Brady F., Chang C.H., Lewandowski K., Russell M.L. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990, 17:809-812.
36. McHugh N.J., Balachrishnan C., Jones S.M. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003, 42:778-783.
37. Khan M., Schentag C., Gladman D. Clinical and radiological changes during psoriatic arthritis disease progression: working toward classification criteria. J Rheumatol 2003, 30:1022-1026.
38. Kane D., Stafford L., Bresniham B., Fitzgerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003, 42:1460-1468.
39. Queiro-Silva R., Torre-Alonso J.C., Tinture-Eguren T., Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003, 62:68-70.
40. Bond S.J., Farewell V.T., Schentag C.T., Gladman D.D. Predictors for radiological damage in psoriatic arthritis. Results from a single centre. Ann Rheum Dis 2007, 66:370-376.
41. Gladman D.D. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008, 26(Suppl. 51):S62-S65.
42. Gladman D.D. Disability and quality of life considerations. Psoriatic arthritis. Psoriasis and psoriatic arthritis: an integrated approach 2005, 118-123. Springer-Verlag, Heidelberg, Germany. G.B. Gordon, E. Ruderman (Eds.).
43. Moll J.M., Wright V. Familial occurrence of PsA. Ann Rheum Dis 1973, 32:181-201.
44. Chandran V., Schentag C.T., Brockbank J., Pellett F.J., Shanmugrajah S., Toloza SMA, et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 2009, 68:664-667.
45. Callis Duffin K., Chandran V., Gladman D.D., Krueger G.G., Elder J.T., Rahman P. Genetics of psoriasis and psoriatic arthritis: Update and Future Direction (GRAPPA 2007). J Rheumatol 2008, 35:1449-1453.
46. Prinz J.C. Psoriasis vulgaris-a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001, 26:326-332.
47. Vasey F.B., Seleznick M.J., Fenske N.A., Espinoza L.R. New signposts on the road to understanding psoriatic arthritis. J Rheumatol 1989, 16:1405-1407.
48. Martin M.P., Nelson G., Lee J.-H., Pellett F., Gao X., Wade J., et al. Susceptibility to psoriatic arthritis: influence of activating killer immunoglobulin-like receptor genes in the absence of their corresponding HLA ligands. J Immunol 2002, 169:2818-2822.
49. Olivieri I., Padula S., D'Angelo S., Scarpa R. Role of trauma in psoriatic arthritis. J Rheumatol 2008, 35:2085-2087.
50. Veale D., Barrell M., Fitzgerald O. Mechanisms of joint sparing in a patient with unilateral psoriatic arthritis and a long-standing hemiplegia. Br J Rheumatol 1993, 32:413-416.
51. Veale D., Yanni G., Rogers S., Barnes L., Bresnihan B., Fitzgerald O. Reduced synovial membrane macrophage numbers, ELAM1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993, 36:893-900.
52. Ritchlin C., Haas-Smith S.A., Hicks D. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25:1544-1552.
53. Espinoza L.R., Aguilar J.L., Espinoza C.G., Cuéllar M.L., Scopelitis E., Silveira L.H. Fibroblast function in psoriatic arthritis. I: Alteration of cell kinetics and growth factor responses. J Rheumatol 1994, 21:1502-1506.
54. Espinoza L.R., Aguilar J.L., Espinoza C.G., Scopelitis E., Silveira L.H., Grotendorst G.R. Fibroblast function in psoriatic arthritis. II: Increased expression of PDGF receptors and increased production of GF and cytokines. J Rheumatol 1994, 21:1507-1511.
55. Costello P., Bresnihan B., O'Farrell C., Fitzgerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 1999, 26:1117-1124.
56. Anandarajah A.P., Ritchlin C.T. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2004, 16:338-343.
57. Ritchlin C.T., Haas-Smith S.A., Li P., Hicks D.G., Schwarz E.M. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821-831.
58. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008, 128:1064-1067.
59. Neumüller J., Dunky A., Burtscher H., Jilch R., Menzel J.E. Interaction of monocytes from patients with psoriatic arthritis with cultured microvascular endothelial cells. Clin Immunol 2001, 98:143-152.
60. Fraser A., Fearon U., Reece R., Emery P., Veale D.J. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001, 44:2024-2028.
61. Hitchon C.A., Danning C.L., Illei G.G., El Gabalawy H.S., Boumpas D.T. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis. J Rheumatol 2002, 29:107-117.
62. Hueber A.J., McInnes I.B. Immune regulation in psoriasis and psoriatic arthritis-recent developments. Immunol Lett 2007, 114:59-65.
63. Sarzi-Puttini P., Santandrea S., Boccassini L., Panni B., Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001, 19:S17-S20.
64. Griffiths C.E. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br J Rheumatol 1997, 36:409-410.
65. Chan F.K. The David Y. Graham lecture: use of nonsteroidal anti-inflammatory drugs in a COX-2 restricted environment. Am J Gastroenterol 2008, 103:221-227.
66. Eder L., Chandran V., Ueng J., Bhella S., Schentag C.T., Lee K.A., et al. Predictors of response to intra-articular steroids in psoriatic arthritis. Arthritis Rheum 2008, 58:3991.
67. Baker H., Ryan T.J. Generalized pustular psoriasis: a clinical and epidemiological study of 104 cases. Br J Dermatol 1968, 80:771-793.
68. Nash P., Clegg D.O. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005, 64(Suppl. 2):274-277.
69. Black R.L., O'Brien W.M., Vanscott E.J., Auerbach R., Eisen A.J., Bunim J.J. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964, 189:743-747.
70. Willkens R.F., Williams H.J., Ward J.R., Egger M.J., Reading J.C., Clements P.J., et al. Randomized, double blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984, 27:376-381.
71. Soriano E.R., McHugh N.J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006, 33:1422-1430.
72. Abu-Shakra M., Gladman D.D., Thorne J.C., Long J., Gough J., Farewell V.T. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995, 22:241-245.
73. Chandran V., Schentag C.T., Gladman D.D. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008, 35:469-471.
74. Ellis C.N., Fradin M.S., Messana J.M., Brown M.D., Siegel M.T., Hartley A.H., et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991, 324:277-284.
75. Salvarani C., Macchioni P., Olivieri I., Marchesoni A., Cutolo M., Ferraccioli G., et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001, 28:2274-2282.
76. Spadaro A., Riccieri V., Sili-Scavalli A., Sensi F., Taccari E., Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995, 13:589-593.
77. Fraser A.D., van Kuijk A.W., Westhovens R., Karim Z., Wakefield R., Gerards A.H., et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005, 64:859-864.
78. Levy J.J., Paulus H.E., Barnett E.V., et al. A double blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 1972, 15:116-117.
79. Lee J.C.T., Gladman D.D., Schentag C.T., Cook R.J. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol 2001, 7:160-165.
80. Kaltwasser J.P., Nash P., Gladman D., Rosen C.F., Behrens F., Jones P., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004, 50:1939-1950.
81. Carette S., Calin A., McCafferty J.P., Wallin B.A. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum 1989, 32:158-165.
82. Palit J., Hill J., Capell H.A., Carey J., Daunt S.O., Cawley M.I., et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990, 29:280-283.
83. Schrader P., Mooser G., Peter R.U., Puhl W. [Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil]. Z Rheumatol 2002, 61:545-550.
84. Grundmann-Kollmann M., Mooser G., Schraeder P., Zollner T., Kaskel P., Ochsendorf F., et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000, 42:835-837.
85. Hopkins R., Bird H.A., Jones H., Hill J., Surrall K.E., Astbury C., et al. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis 1985, 44:189-193.
86. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B.K., Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390.
87. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
88. Antoni C.E., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G.R., Schneider U., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227-1236.
89. Antoni C., Krueger G.G., de Vlam K., Birbara C., Beutler A., Guzzo C., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157.
90. Kavanaugh A., Antoni C., Krueger G.G., Yan S., Bala M., Dooley L.T., et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006, 65:471-477.
91. Kavanaugh A., Krueger G.G., Beutler A., Guzzo C., Zhou B., Dooley L.T., et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66:498-505.
92. Antoni C.E., Kavanaugh A., van der Heijde D., Beutler A., Keenan G., Zhou B., et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008, 35:869-876.
93. Kavanaugh A., Antoni C., Mease P., Gladman D., Yan S., Bala M., et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006, 33:2254-2259.
94. Kavanaugh A., Krueger G.G., Beutler A., Guzzo C., Zhou B., Dooley L.T., et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through one year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66:498-505.
95. van der Heijde D., Kavanaugh A., Gladman D.D., Antoni C., Krueger C.C., Guzzo C., et al. IMPACT 2 Study Group Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 66:2698-2707.
96. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of The ADEPT Trial. Arthritis Rheum 2005, 52:3279-3289.
97. Gladman D.D., Mease P.J., Cifaldi M.A., Perdok R.J., Sasso E., Medich J. Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: functional outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2007, 66:166-168.
98. Gladman D.D., Mease P.J., Ritchlin C.T., Choy E.H.S., Sharp J.T., Ory P.A., et al. Adalimumab for long-term treatment of psoriatic arthritis: 48-week data and subanalysis from ADEPT. Arthritis Rheum 2007, 56:476-488.
99. Kavanaugh A., McInnes I., Mease P., Krueger G.G., Gladman D., Gomez-Reino J., et al. Golimumab, a new human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Arthritis Rheum 2009, 60:976-986.
100. Gladman D., Kavanaugh A., McInnes I., Mease P., Gomez-Reino J.J., Papp K., et al. Golimumab, a new human TNF-alpha antibody administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: nail enthesitis, and dactylitis response in the randomized placebo-controlled Go-Reveal study. Ann Rheum Dis 2008, 67(Suppl. 2):526.
101. Kavanaugh A., Mease P., Krueger G.G., Gladman D., Gomez-Reino J.J., Papp K., et al. Golimumab, a new human TNG alpha antibody administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52 week efficacy and safety results of the randomized placebo-controlled Go-Reveal study. Ann Rheum Dis 2008, 67(Suppl. 2):99.
102. Askling J., Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:334-339.
103. Rohekar S., Tom B.D., Hassa A., Schentag C., Farewell V.T., Gladman D.D. Malignancy in psoriatic arthritis. Arthritis Rheum 2008, 58:82-87.
104. Saad A.A., Symmons D.P.M., Noyce P.R., Ashcroft D.M. Risk and benefits of tumour necrosis factor-α inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008, 35:883-890.
105. Gottlieb A.B., Mendelsohn A., Shen Y.K., Menter A. Randomized, placebo-controlled phase 2 study of ustekinumab, a human IL-12/23 monoclonal antibody in psoriatic arthritis. Ann Rheum Dis 2008, 67(Suppl. 2):99.
106. Mease P.J., Gladman D.D., Keystone E.C. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006, 54:1638-1645.
107. Lebwohl M., Tyring S.K., Hamilton T.K., Toth D., Glazer S., Tawfik N.H., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003, 349:2004-2013.
108. Papp K.A., Caro I., Leung H.M., Garovoy M., Mease P.J. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007, 11:57-66.
109. Viguier M., Richette P., Aubin F., Beylot-Barry M., Lahfa M., Bedane C., et al. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. Arthritis Rheum 2008, 58:1796-1802.
110. Menter A., Gottlieb A., Feldman S.R., Van Voorhees A.S., Leonardi C.L., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008, 58:826-850.
111. Gottlieb A., Korman N.J., Gordon K.B., Feldman S.R., Lebwohl M., Koo J.Y., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008, 58:851-864.
112. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Boehncke WH, de Vlam K, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis epub ahead of print 24/10/08.